Drugs / QEL-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05234190 | Jan 2022 → Feb 2026 overdue | liver failure, transplant rejection | Quell Therapeutics Limited | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-03-03 | Quell Therapeutics Limited | Results Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study quell-tx.com ↗
Interim data from LIBERATE suggests evidence of QEL-001 safety and clinical activity enabling IS minimization: 9 patients dosed to date with QEL-001: 3 safety cohort patients and 6 expansion cohort patients, with no serious adverse events (SAEs), no dose-limiting toxicity (DLT) or drug-related adverse events (AEs) in the study period. |
| 2024-10-22 | Quell Therapeutics Limited | Results Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses quell-tx.com ↗
The clinical data being presented from the safety cohort demonstrate that QEL-001 is well-tolerated, has shown cell persistence post infusion up to six months and has a stable phenotype over time via FOXP3 and HELIOS expression. |
| 2024-06-05 | Quell Therapeutics Limited | Results Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR- Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients quell-tx.com ↗
Infusion of QEL-001 was shown to be safe and well tolerated in the safety cohort (n=3) |
| 2024-05-02 | Quell Therapeutics Limited | Results Quell Therapeutics Highlights Clinical Potential of QEL-001 and its Multi-Modular Treg Cell Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting quell-tx.com ↗
These data provide a rigorous scientific foundation for our engineered Treg cell therapy approach and we are delighted that these desired characteristics are beginning to be validated clinically through initial findings with QEL-001 in our ongoing Phase 1/2 LIBERATE trial. |
| 2021-10-27 | Quell Therapeutics Limited | Regulatory Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy quell-tx.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QEL-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05234190 ↗ |
| Modality | Cell therapy | “autologous CAR T regulatory (CAR-Treg)” NCT05234190 ↗ |
| Route | Intravenous | “Treatment will be given via an IV infusion.” NCT05234190 ↗ |